Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, People's Republic of China.
Suzhou Medical College, Soochow University, Suzhou, People's Republic of China.
Hematology. 2023 Dec;28(1):2231765. doi: 10.1080/16078454.2023.2231765.
Triptolide (TPL) is a diterpenoid isolated from the traditional Chinese medicine Tripterygium wilfordii. It has powerful antitumor, immunosuppressive and anti-inflammatory properties. Recent studies have shown that TPL can induce apoptosis of hematological tumor cells, inhibit their proliferation and survival, promote autophagy and ferroptosis, and enhance the efficacy of traditional chemotherapy and targeted therapies. Various molecules and signaling pathways, such as NF-κB, BCR-ABL, and Caspase, are involved in inducing apoptosis of leukemia cells. To solve the water solubility and toxic side effects of TPL, low-dose TPL (IC20) combined with chemotherapy drugs and various TPL derivatives have entered preclinical studies. This review discusses advances in molecular mechanism, the development and utilization of structural analogues of TPL in hematologic tumors in the past two decades, and clinical applications.
雷公藤红素(TPL)是一种从传统中药雷公藤中分离得到的二萜类化合物。它具有强大的抗肿瘤、免疫抑制和抗炎特性。最近的研究表明,TPL 可以诱导血液肿瘤细胞凋亡,抑制其增殖和存活,促进自噬和铁死亡,并增强传统化疗和靶向治疗的疗效。多种分子和信号通路,如 NF-κB、BCR-ABL 和 Caspase,参与诱导白血病细胞凋亡。为了解决 TPL 的水溶性和毒副作用问题,低剂量 TPL(IC20)与化疗药物和各种 TPL 衍生物已进入临床前研究。本文综述了过去 20 年来 TPL 在血液肿瘤中的分子机制、结构类似物的开发和利用以及临床应用的进展。